BioMarin Pharmaceutical CEO Sells $135,460 in Stock (BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 2,000 shares of BioMarin Pharmaceutical stock on the open market in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $67.73, for a total value of $135,460.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 2.67% on Friday, hitting $66.36. The stock had a trading volume of 2,042,596 shares. BioMarin Pharmaceutical has a one year low of $36.28 and a one year high of $80.67. The stock’s 50-day moving average is $71.71 and its 200-day moving average is $64.91. The company’s market cap is $9.297 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, July 25th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.29) by $0.13. The company had revenue of $136.80 million for the quarter, compared to the consensus estimate of $134.33 million. During the same quarter last year, the company posted ($0.27) earnings per share. BioMarin Pharmaceutical’s revenue was up 10.3% compared to the same quarter last year. On average, analysts predict that BioMarin Pharmaceutical will post $-1.15 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on BMRN shares. Analysts at Wells Fargo & Co. reiterated a “market perform” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, September 27th. Separately, analysts at Wedbush reiterated a “hold” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, September 20th. They now have a $88.00 price target on the stock. Finally, analysts at William Blair reiterated a “hold” rating on shares of BioMarin Pharmaceutical in a research note to investors on Wednesday, September 18th. They now have a $88.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $72.68.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.